Lung Foundation Australia, in collaboration with the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF), look forward to presenting this webinar to explore the latest in pulmonary fibrosis clinical trials.
In this live webinar featuring A/Prof Vidya Navaratnam, Respiratory Physician, and Prof Ian Glaspole, Respiratory & Sleep Disorders Physician, you will discover what’s new and upcoming in PF/ILD clinical trials and learn how the participation process works.
During this session, we’ll cover:
- The latest insights into current PF/ILD clinical trials, and what’s on the horizon
- Insights into clinical trial participation and how to get involved
- An overview of the Pulmonary Fibrosis Australasian Clinical Trials (PACT) Network
You’ll also have the opportunity to ask questions and engage in real-time discussions.
Meet our speakers
Associate Professor Vidya Navaratnam
Associate Prof Vidya Navaratnam is a thoracic and lung transplant physician and a trained epidemiologist. Her research interests include using routinely collected health information to conduct large epidemiological studies and target trial emulation. She is also passionate about clinical trials and is principal investigator to commercial and investigator led trials at the Institute for Respiratory Health. A/Prof Navaratnam has international clinical and research experience in lung fibrosis and collaborates closely with other researchers in the CRE-PF.
Professor Ian Glaspole
Ian Glaspole is a clinician academic, head of the Interstitial lung disease service at the Alfred Hospital, Melbourne and an Adjunct Clinical Professor in the Central and Eastern Clinical School, Monash University. He completed his advanced training in respiratory medicine at the Royal Brompton Hospital in London and his doctoral research at the Alfred Hospital. Shortly after, he established the first dedicated interstitial lung disease service in Australia, at the Alfred Hospital.
He is the current chair of the Pulmonary Fibrosis Australasian Clinical Trials Network (PACT). He has been a chief investigator in five NHMRC grants and three MRFF grants with grant funding totalling more than $25 million. He has participated as a principal investigator in over 30 ILD clinical trials and has also acted as a consultant and steering committee member to multiple pharmaceutical companies involved in ILD drug development. He has authored 141 peer-reviewed manuscripts, including 3 position statements, with 58 publications in the last five years.
This webinar is proudly supported by
